Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

Journal of Clinical Investigation

Volumn 107, Issue 4, 2001, Pages 477-484

  Knutson, K L ^a   Schiffman, K ^a   Disis, M L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; HUMAN; LYMPHOCYTE COUNT; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; VACCINATION;

EID: 0035113705     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11752     Document Type: Article

References (42)

1. Human tumor antigens for cancer vaccine development
2. HER-2/neu oncogenic protein: Issues in vaccine development
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
4. Prognostic importance of c-erbB-2 expression in breast cancer
5. In vitro generation of human cyrolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein
6. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
7. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide
8. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay
9. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors
10. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
11. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
12. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malania peptides
13. Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide
14. The central role of CD4(+) T cells in the antitumor immune response
15. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
16. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
17. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help
18. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene
19. Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein
20. Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants
21. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
22. Immunity to the HER-2/neu oncogenic protein
23. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture
24. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
25. Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood
26. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
27. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
28. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
29. Isolation of HER-2/neu (HER2) specific T cell clones from a cancer patient following immunization with a HER2 peptide vaccine
30. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
31. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
32. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes
33. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
34. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
35. The optimization of helper T lymphocyte (HTL) function in vaccine development
36. Universally immunogenic T cell epitopes: Promiscuous binding to human MHC class II and promiscuous recognition by T cells
37. Peptide immunization in humans: A combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL)
38. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay
39. Therapy with cultured T cells: Principles revisited
40. Use of helper T cell inducing peptides from conserved regions in HIV-1 env in a noncovalent mixture with a CTL-inducing V3-loop peptide for in vivo induction of longlasting systemic CTL response
41. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes
42. Long-term survival of anti-tumor lymphocytes generated by vaccination of patients with melanoma with a peptide vaccine